Companion Animals: Reservoir of Carbapenem Resistance: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Joana Cabral Moreira da Silva.

The dissemination of antimicrobial-resistance is a major global threat affecting both human and animal health. Carbapenems are human use β-lactams of last resort; thus the dissemination of carbapenemase-producing (CP) bacteria creates severe limitations for the treatment of multidrug-resistant bacteria in hospitalized patients. Even though carbapenems are not routinely used in veterinary medicine, reports of infection or colonization by carbapenemase-producing Enterobacterales in companion animals are being reported. NDM-5 and OXA-48-like carbapenemases are among the most frequently reported in companion animals. Like in humans, Escherichia coli and Klebsiella pneumoniae are the most represented CP Enterobacterales found in companion animals, alongside with Acinetobacter baumannii. Considering that the detection of carbapenemase-producing Enterobacterales presents several difficulties, misdiagnosis of CP bacteria in companion animals may lead to important animal and public-health consequences. It is of the upmost importance to ensure an adequate monitoring and detection of CP bacteria in veterinary microbiology in order to safeguard animal health and minimise its dissemination to humans and the environment. 

  • companion animals
  • Enterobacterales
  • carbapenemase detection methods

1. Introduction

Carbapenems are β-lactam antibiotics with broad antimicrobial spectrum. With the emergence of Extended Spectrum β-lactamases (ESBLs), carbapenems became the antibiotics of last resort for treatment of human patients with ESBL-producing Enterobacterales infections [1]. Although carbapenems are not hydrolysed by most β-lactamases, their effectiveness was seriously compromised by the emergency of carbapenem-hydrolysing enzymes, the carbapenemases [1,2][1][2]. The most important carbapenemases belong to three different Amber classes [2]: (i) class A, including the KPC, IMI/NMC, SFC, GES type enzymes [1,2][1][2]; (ii) class B, including VIM, IMP, and NDM metallo-β-lactamases (MBL) [3]; and (iii) class D, including OXA-48-like type enzymes [4].
Regulation on the use of carbapenems in animals varies worldwide and they do not belong to the OIE List of Antimicrobial Agents of Veterinary Importance [5]. According to the European Medicine Agency categorization of antibiotics for animal use, carbapenems are included in category A (“Avoid”), meaning they are not authorized for use in veterinary medicine in the European Union (EU), except in exceptional clinical cases in companion animals, under the cascade according to Article 112 of the veterinary medicinal products Regulation 2019 of the European Union Legislation [6]. Reports of carbapenemase-producing (CP) and carbapenem-resistant Enterobacterales (CRE) detection among companion animals are emerging worldwide (Table 1). The identification of CP bacteria in companion animals, which have significant direct contact with humans, has raised public health concern as animals may constitute an important reservoir of carbapenems resistance genes and contribute to its dissemination [7]. Very recently, the building of an European Antimicrobial Resistance Surveillance network in veterinary medicine (EARS-Vet) has been reported [8]. However, carbapenem resistance epidemiology remains quite unknow, as, unlike in human medicine, no global surveillance protocol is currently in place for companion animal veterinary medicine. Furthermore, the detection of CP bacteria relying on antimicrobial susceptibility testing alone (AST) presents several pitfalls leading to its possible miss detection in veterinary medicine. Appropriate monitoring and detection of antimicrobial resistance against these critically important antimicrobials in veterinary medicine is of the utmost importance to avoid treatment failure and prevent its dissemination to humans and the environment. However, there is a lack of recommendations directed specifically to the veterinary medicine needs in the published literature.

2. Carbapenemase-Producing Bacteria in Companion Animals

To ouresearchers' best knowledge, more than 25 reports of CP bacteria in dogs and cats have been published worldwide. These include, both infection and colonization CP isolates harbouring KPC, VIM, IMP, NDM, or OXA β-lactamases (Table 1). Briefly, three studies detected KPC-producing Escherichia coli and Klebsiella pneumoniae from dogs in Brazil and in Enterobacter xiangfangensis from a dog in the United States [9,10,11][9][10][11]. A IMP-4-enzyme in Salmonella isolates was recovered from a cat’s faecal samples in Australia [12], VIM-2 in Pseudomonas aeruginosa from dogs with pyoderma and otitis in South Korea [13] and VIM-1 in K. pneumoniae from dogs in Spain [14]. A number of NDM-5-producing E. coli have been found in dogs and cats [15,16,17,18[15][16][17][18][19][20][21][22],19,20,21,22], one NDM-1-producing Acinetobacter radioresistens was detected in a dog, six NDM-1-producing E. coli from dogs and cats in the United States, two NDM-1-producing E. coli from a dog in China, and finally one NDM-9 from a farm dog in China [23,24,25][23][24][25]. Several OXA-48-like carbapenemase-producing E. coli, K. pneumoniae, Klebsiella oxytoca, and Enterobacter cloacae isolates were recovered from dogs, cats, and horses, representing one of the most frequent carbapenemases detected in companion animals alongside with NDM-5 (Table 1) [17,26,27,28,29,30,31,32][17][26][27][28][29][30][31][32]. In addition, OXA-23- and OXA-66-producing Acinetobacter baumannii were isolated from clinical samples from dogs and cats [23,33,34][23][33][34]. Interestingly, although the detection of CP bacteria in companion animals dates to at least 2009, detection methods vary widely between studies, with the use of selective culture media being the most frequent for the detection of commensal CP isolates, while antimicrobial susceptibility testing alone (AST) is the main method used for the detection of CP isolates in infection cases (Table 1). Another important finding is that most CP bacterial species isolated from companion animals belong to the priority 1 (“critical”) category within the WHO priority pathogens list [35], thus highlighting the importance of properly monitoring and effectively detecting these carbapenem resistance mechanisms in companion animals.
Table 1.
Carbapenemases found in companion animals across the world.
Enzyme Year Country Host Source Bacterial Species Detection Methods Refs.
Table 2).
Table 2.
Common β-lactam hydrolysis profile of carbapenemases.
Amber

Class		 Representative

Carbapenemase

Type		 Hydrolysis Profile Refs.
Narrow

Spectrum

Cephalosporins		 Extended

Spectrum

Cephalosporins		 Imipenem * Meropenem *
IMP-4 2016 Australia Cats Commensal Salmonella

enterica

serovar

Typhimurium		 AST [12]
Class A KPC + + + + [2,9][2][9]
KPC-2 2018 Brazil Dog Infection

(UTI)		 Escherichia coli Imipenem synergy test, modified Hodge testing, PCR [9]
Class B IMP, VIM, NDM, + + + + [3] KPC-2 2021 Brazil Dog Infection

(UTI)		 Klebsiella

pneumoniae		 Imipenem synergy test, AST [
Class D OXA-48-like10 + - Variable 1]
- [4,38,39][4][38][39] KPC-4 2018 USA Dog Infection

(UTI, SSTI)		 Enterobacter xiangfangensis Biochemical Tests [11
OXA-23-like]
+ + + + [4] NDM-1 2013 United States Dogs,

Cats		 Infection

(SSTI, UTI)		 Escherichia coli AST [24]
NDM-1 2017 China Dogs Commensal Escherichia coli Selective culture media [16,25][16][25]
NDM−1 2018 Italy Dog Commensal Acinetobacter

radioresistens		 Selective culture media [23]
NDM-5 2016 Algeria Dogs Commensal Escherichia coli PCR [17]
NDM-5 2017 China Dogs Commensal Escherichia coli Selective culture media [16]
NDM-5 2019 United Kingdom Dog Infection

(SSTI)		 Escherichia coli AST [19]
NDM-5 2018 Finland Dogs Infection

(Otitis externa)		 Escherichia coli AST followed by

modified Hodge testing, UV spectrometric

detection of imipenem hydrolysis		 [18]
NDM-5 2021 Italy Dog Infection

(UTI)		 Escherichia coli Meropenem synergy test [15]
NDM-5 2018 United States Dog Infection

(URTI)		 Escherichia coli AST [20]
NDM-5 2018 United States Dogs,

Cats		 Infection

(UTI, URTI)		 Escherichia coli AST [22]
NDM-5 2018 South Korea Dog,

Cat		 Commensal Escherichia coli AST, PCR [21]
NDM-9 2017 China Dog Commensal Escherichia coli Selective culture media [16]
OXA-48 2009–2010 Germany Dogs,

Cats,

Horses		 Infection Escherichia coli, Klebsiella

pneumoniae,

Enterobacter

cloacae		 Selective culture media for cephalosporin resistance,

PCR		 [36]
OXA-48 2013 Germany Dog Commensal,

Infection

(UTI, SSTI, URTI, CRBSI)		 Klebsiella

pneumoniae,

Escherichia coli		 AST [29]
OXA-48 2016 United States Dogs,

Cats		 Infection

(UTI, SSTI, Genital tract)		 Escherichia coli AST [31]
OXA-48 2016 Algeria Dogs Commensal Escherichia coli PCR [17]
OXA-48 2017 Algeria Dogs,

Cat,

Horses,

Pet birds		 Commensal Enterobacter

cloacae,

Escherichia coli, Klebsiella

pneumoniae		 Selective culture media [32]
OXA-48 2017 France Dog Commensal Escherichia coli Selective culture media [30]
OXA-48 2018 Germany Dogs,

Cats,

Horses		 Infection

(UTI, SSTI, genital tract, otitis, URTI)		 Klebsiella

pneumoniae,

Enterobacter

cloacae,

Escherichia coli, Klebsiella oxytoca		 Selective culture media [28]
OXA-181 2018 Switzerland Dogs,

Cats		 Commensal Escherichia coli Selective culture media [26]
OXA-181 2020 Portugal Dog Commensal Escherichia coli Selective culture media and AST [27]
OXA-181 2021 Portugal Cat Infection

(SSTI)		 Klebsiella

pneumoniae		 Selective culture media and AST [37]
OXA-23 2014 Portugal Cat Infection

(UTI)		 Acinetobacter

baumannii		 AST [33]
OXA-23 2017 Germany Dogs,

Cats		 Infection

(UTI, suppurate inflammation)		 Acinetobacter

baumannii		 Selective culture media [34]
OXA−23 2018 Italy Dogs,

Cats		 Commensal Acinetobacter

baumanni		 Selective culture media [23]
OXA-66 2017 Germany Dogs,

Cats		 Infection

(UTI, SSTI, URTI, CRBSI, suppurate inflammation)		 Acinetobacter

baumannii		 Selective culture media [34]
VIM-1 2016 Spain Dog Commensal Klebsiella

pneumoniae		 Selective culture media, Meropenem synergy test [14]
VIM-2 2018 South Korea Dog Infection

(SSTI)		 Pseudomonas

aeruginosa		 AST [13]
AST, antimicrobial susceptibility testing; CRBSI, catheter-related bloodstream infection; SSTI, skin soft tissue infection; URTI, upper respiratory tract infections; UTI, urinary tract infection.

3. Phenotypic Characteristics of Carbapenemases and Their Genetic Background in Isolates from Companion Animals

The β-lactam resistance phenotype of CP isolates can vary depending on the type of carbapenemase and its hydrolysing activity (
* Imipenem and meropenem representative MIC values for carbapenemase-producing isolates from companion animals are listed in Table S1. 1 Imipenem susceptible in OXA-48-like has been reported.

3.1. Serine Carbapenemases

Serine carbapenemases of molecular (Ambler) class A corresponds to the KPC, IMI/NMC, SFC, and GES enzymes that have a hydrolytic mechanism involving an active site serine at position 70 (Ambler numbering of class A β-lactamases), conferring resistance to first-, second-, and third-generation cephalosporins, imipenem, and meropenem [2]. Class A carbapenemases have been rarely detected in companion animals, the KPC enzyme being the only one reported until now from dogs with UTI and SSTI (Table 1). In K. pneumoniae and E. coli from dogs, the blaKPC-2 gene was found in Tn4401 transposons contained in IncN plasmids [9,10][9][10] and the blaKPC-4 gene was detected in an IncHI2 plasmid in the context of Tn4401b transposon in E. xiangfangensis isolated from a dog’s clinical samples [11].

3.2. Metallo-β-Lactamases

Class B carbapenemases have a critical clinical significance due to their ability to hydrolyse all β-lactams (Table 2) [3,40][3][40]. So far, more than 50 allelic β-lactamase-conferring imipenem resistance (IMP) variants are listed at GenBank DNA sequence database. However, only IMP-4 has been reported among companion animals, namely, cats, in Salmonella enterica serovar Typhimurium (Table 1) [12]. The IMP-4 coding gene was located on a gene cassette (blaIMP-4-qacG-aacA4-catB3) in a class 1 integron, associated with a conjugative plasmid IncHI2, also carrying other resistance genes, such as tetA (mediating resistance to tetracycline), aac (resistance to aminoglycosides), cat (chloramphenicol resistance), sul (sulphonamide resistance), blaOXA (different serine oxacillinases), and blaTEM-1 (narrow-spectrum β-lactamases) [12]. Verona Integron-encoded Metallo-β-Lactamase (VIM) enzymes are the second most common Class B carbapenemase detected in companion animals (Table 1). VIM-1 and VIM-2 were described in K. pneumoniae and P. aeruginosa isolates from dogs, respectively; both located in class 1 integrons incorporated on untyped plasmids [13,14][13][14]. The blaNDM genes pose a serious public health concern, since most common plasmids associated with its spread often have various antibiotic resistance genes resulting in multidrug resistance phenotypes [18,19,41][18][19][41]. Until now, 28 variants have been described, with resistance against all β-lactams expect monobactams [42]. In companion animals only NDM-1 and NDM-5 have been described so far (Table 1), the latter being more frequent. For one metallo-β-lactamase NDM-1, the encoding gene was located in a transposon Tn125 (composed of blaNDM-1-bleMBL-trpF-TAT-cutA1-groES-groEL-insE-Δpac genes between a pair of ISAba125), integrated in the chromosome of an A. radioresistens isolated from a dog in Italy [23]. This Tn125 transposon usually encompasses blaNDM genes with two flanking ISAba125 elements, and in companion animals it was also found in blaNDM-5 carrying strains [16,23][16][23]. A NDM-1-producing E. coli isolate harboured blaNDM-1 in another genetic region, which was not flanked by ISAba125 elements downstream of the resistance gene [25]. NDM-5 metallo-β-lactamase differs from NDM-1 by four amino acids and has been found in the chromosome of an integrated IncF plasmid, from an E .coli isolate causing skin and soft tissue infection on a dog in the United Kingdom [19]. In the United States, the blaNDM-5-encoding gene has been found on IncFII-type plasmids [20[20][22],22], whereas in South Korea it was described in an IncX3-type plasmid [21] with the surrounding genetic environment of ISAba125-blaNDM-5-bleMBL-trpF-TAT-ISCR26.

3.3. Oxacillinases

The class D, carbapenem-hydrolysing OXA-48 and its variants, namely, OXA-181, are one of the most common in veterinary settings (Table 1). The OXA-181 variant weakly hydrolyses both carbapenem and extended-spectrum cephalosporins and differs from OXA-48 at four amino acid substitution, yet its kinetic properties appear broadly similar to OXA-48 [43,44,45][43][44][45]. These enzymes can be associated more with different β-lactam hydrolysis profiles than the other serine-metallo-β-lactamases, making its accurate detection difficult. By possibly being susceptible in vitro to meropenem and imipenem (Table 2), two widely used surrogates to identify carbapenem resistance in clinical microbiology, carbapenem-resistant bacteria harbouring OXA-48-like carbapenemases may easily be misdiagnosed as ESBL-producers, which may lead to treatment failure. OXA-48-coding genes in CP isolates have been associated with no other resistance genes; or with extended-spectrum β-lactamases coding genes, thus conferring either low or high MIC against carbapenems [46]. High-level resistance to carbapenems has also been observed [31] that may be associated with the combination of these carbapenemases with outer membrane lack of permeability [47]. Importantly, regardless of the carbapenem susceptibility profile detected in vitro, carbapenem therapy is not reliable against OXA-48-like-producing bacteria [45]. In companion animals, the blaOXA-48 gene has been commonly observed on pOXA-48a plasmid, a self-conjugative IncL/M plasmid [28,29,30][28][29][30]. This plasmid has a high conjugation rate, therefore, it can be transferred at a very high frequency across Gram-negative bacteria [41,48][41][48]. Flanking the blaOXA-48 gene is the Tn1999 composite transposon, which cooperates in mobilizing pOXA-48a or closely related plasmids [44,48][44][48]. The blaOXA-181 gene was found to be part of the transposon Tn2013, inserted at the downstream region of ISEcp1, which is a very efficient genetic vehicle for spreading ESBL genes, namely, the blaCTX-M-15 gene [49]. The blaOXA-181 gene has been frequently identified in IncX3 plasmids [26,27][26][27]. The frequency of OXA-48-like-producing bacteria in companion animals (Table 1) and its frequent association with mobile genetic determinants that facilitate its dissemination, highlight the importance of monitoring this resistance mechanism in companion animals. Furthermore, the possible misdiagnosis of OXA-48-like-producing bacteria when using meropenem and imipenem as surrogates may lead to underestimating its frequency and the epidemiological role of companion animals as reservoirs. The blaOXA-23 gene has been reported coming from A. baumannii isolates (Table 1). This gene is often located on transposon Tn2006, but has also been identified in transposon Tn2008 in animals isolates [23,34][23][34]. The blaOXA-23 is usually flanked between ISAba1 insertion sequences, known to promote the expression of blaOXA-23 and blaOXA-51-like genes in A. baumannii for an elevated level sufficient to display carbapenem resistance [23,50][23][50]. In addition to carbapenems, the OXA-23 enzymes can hydrolyse cephalosporins, aminopenicillins, piperacillin, oxacillin, and aztreonam (Table 2) [4].

References

  1. Meletis, G. Carbapenem Resistance: Overview of the Problem and Future Perspectives. Ther. Adv. Infect. Dis. 2016, 3, 15–21.
  2. Nordmann, P.; Dortet, L.; Poirel, L. Carbapenem Resistance in Enterobacteriaceae: Here Is the Storm! Trends Mol. Med. 2012, 18, 263–272.
  3. Walsh, T.R.; Toleman, M.A.; Poirel, L.; Nordmann, P. Metallo-β-Lactamases: The Quiet Before the Storm. Clin. Microbiol. Rev. 2005, 18, 306–325.
  4. Evans, B.A.; Amyes, S.G.B. OXA β-Lactamases. Clin. Microbiol. Rev. 2014, 27, 241–263.
  5. World Organisation for Animal Health (OIE). Oie List of Antimicrobial Agents of Veterinary Importance. In Proceedings of the FAO2/OIE/WHO3 Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance, Geneva, Switzerland, 1–5 December 2003; Volume Xxviii, pp. 1–10.
  6. European Medicines Agency (EMA). Categorisation of Antibiotics in the European Union; European Medicines Agency: London, UK, 2019.
  7. Pomba, C.; Rantala, M.; Greko, C.; Baptiste, K.E.; Catry, B.; van Duijkeren, E.; Mateus, A.; Moreno, M.A.; Pyörälä, S.; Ružauskas, M.; et al. Public Health Risk of Antimicrobial Resistance Transfer from Companion Animals. J. Antimicrob. Chemother. 2017, 72, 957–968.
  8. Mader, R.; Damborg, P.; Amat, J.P.; Bengtsson, B.; Bourély, C.; Broens, E.M.; Busani, L.; Crespo-Robledo, P.; Filippitzi, M.E.; Fitzgerald, W.; et al. Building the European Antimicrobial Resistance Surveillance Network in Veterinary Medicine (EARS-Vet). Eurosurveillance 2021, 26, 2001359.
  9. Sellera, F.P.; Fernandes, M.R.; Ruiz, R.; Falleiros, A.C.M.; Rodrigues, F.P.; Cerdeira, L.; Lincopan, N. Identification of KPC-2-Producing Escherichia Coli in a Companion Animal: A New Challenge for Veterinary Clinicians. J. Antimicrob. Chemother. 2018, 73, 2259–2261.
  10. Sellera, F.P.; Fuga, B.; Fontana, H.; Esposito, F.; Cardoso, B.; Konno, S.; Berl, C.; Cappellanes, M.H.; Cortez, M.; Ikeda, M.; et al. Detection of IncN-PST15 One-Health Plasmid Harbouring BlaKPC-2 in a Hypermucoviscous Klebsiella Pneumoniae CG258 Isolated from an Infected Dog, Brazil. Transbound. Emerg. Dis. 2021, 68, 3083–3088.
  11. Daniels, J.B.; Chen, L.; Grooters, S.V.; Mollenkopf, D.F.; Mathys, D.A.; Pancholi, P.; Kreiswirth, B.N.; Wittum, T.E. Enterobacter cloacae Complex Sequence Type 171 Isolates Expressing KPC-4 Carbapenemase Recovered from Canine Patients in Ohio. Antimicrob. Agents Chemother. 2018, 62, e01161-18.
  12. Abraham, S.; O’Dea, M.; Trott, D.J.; Abraham, R.J.; Hughes, D.; Pang, S.; McKew, G.; Cheong, E.Y.L.; Merlino, J.; Saputra, S.; et al. Isolation and Plasmid Characterization of Carbapenemase (IMP-4) Producing Salmonella enterica Typhimurium from Cats. Sci. Rep. 2016, 6, 35527.
  13. Hyun, J.E.; Chung, T.H.; Hwang, C.Y. Identification of VIM-2 Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Isolated from Dogs with Pyoderma and Otitis in Korea. Vet. Dermatol. 2018, 29, 186-e68.
  14. González-Torralba, A.; Oteo, J.; Asenjo, A.; Bautista, V.; Fuentes, E.; Alós, J.I. Survey of Carbapenemase-Producing Enterobacteriaceae in Companion Dogs in Madrid, Spain. Antimicrob. Agents Chemother. 2016, 60, 2499–2501.
  15. Alba, P.; Taddei, R.; Cordaro, G.; Fontana, M.C.; Toschi, E.; Gaibani, P.; Marani, I.; Giacomi, A.; Diaconu, E.L.; Iurescia, M.; et al. Carbapenemase IncF-Borne BlaNDM-5 Gene in the E. Coli ST167 High-Risk Clone from Canine Clinical Infection, Italy. Vet. Microbiol. 2021, 256, 109045.
  16. Wang, Y.; Zhang, R.; Li, J.; Wu, Z.; Yin, W.; Schwarz, S.; Tyrrell, J.M.; Zheng, Y.; Wang, S.; Shen, Z.; et al. Comprehensive Resistome Analysis Reveals the Prevalence of NDM and MCR-1 in Chinese Poultry Production. Nat. Microbiol. 2017, 2, 16260.
  17. Yousfi, M.; Touati, A.; Mairi, A.; Brasme, L.; Gharout-Sait, A.; Guillard, T.; De Champs, C. Emergence of Carbapenemase-Producing Escherichia Coli Isolated from Companion Animals in Algeria. Microb. Drug Resist. 2016, 22, 342–346.
  18. Grönthal, T.; Österblad, M.; Eklund, M.; Jalava, J.; Nykäsenoja, S.; Pekkanen, K.; Rantala, M. Sharing More than Friendship—Transmission of NDM-5 ST167 and CTX-M-9 ST69 Escherichia Coli between Dogs and Humans in a Family, Finland, 2015. Euro Surveill. 2018, 23, 1700497.
  19. Reynolds, M.E.; Phan, H.T.T.; George, S.; Hubbard, A.T.M.; Stoesser, N.; Maciuca, I.E.; Crook, D.W.; Timofte, D. Occurrence and Characterization of Escherichia coli ST410 Co-Harbouring BlaNDM-5, BlaCMY-42 and BlaTEM-190 in a Dog from the UK. J. Antimicrob. Chemother. 2019, 74, 1207–1211.
  20. Tyson, G.H.; Li, C.; Ceric, O.; Reimschuessel, R.; Cole, S.; Peak, L.; Rankin, S.C. Complete Genome Sequence of a Carbapenem-Resistant Escherichia coli Isolate with BlaNDM-5 from a Dog in the United States. Microbiol. Resour. Announc. 2019, 8, 22–23.
  21. Hong, J.S.; Song, W.; Jeong, S.H. Molecular Characteristics of NDM-5-Producing Escherichia coli from a Cat and a Dog in South Korea. Microb. Drug Resist. 2020, 26, 1005–1008.
  22. Cole, S.D.; Peak, L.; Tyson, G.H.; Reimschuessel, R.; Ceric, O.; Rankin, S.C. New Delhi Metallo-β-Lactamase-5–Producing Escherichia coli in Companion Animals, United States. Emerg. Infect. Dis. 2020, 26, 381–383.
  23. Gentilini, F.; Turba, M.E.; Pasquali, F.; Mion, D.; Romagnoli, N.; Zambon, E.; Terni, D.; Peirano, G.; Pitout, J.D.D.; Parisi, A.; et al. Hospitalized Pets as a Source of Carbapenem-Resistance. Front. Microbiol. 2018, 9, 2872.
  24. Shaheen, B.W.; Nayak, R.; Boothe, D.M. Emergence of a New Delhi Metallo-β-Lactamase (NDM-1)-Encoding Gene in Clinical Escherichia coli Isolates Recovered from Companion Animals in the United States. Antimicrob. Agents Chemother. 2013, 57, 2902–2903.
  25. Cui, L.; Lei, L.; Lv, Y.; Zhang, R.; Liu, X.; Li, M.; Zhang, F.; Wang, Y. blaNDM-1-Producing Multidrug-Resistant Escherichia coli Isolated from a Companion Dog in China. J. Glob. Antimicrob. Resist. 2018, 13, 24–27.
  26. Nigg, A.; Brilhante, M.; Dazio, V.; Clément, M.; Collaud, A.; Brawand, S.G.; Willi, B.; Endimiani, A.; Schuller, S.; Perreten, V. Shedding of OXA-181 Carbapenemase-Producing Escherichia coli from Companion Animals after Hospitalisation in Switzerland: An Outbreak in 2018. Eurosurveillance 2019, 24, 1900071.
  27. Brilhante, M.; Menezes, J.; Belas, A.; Feudi, C.; Schwarz, S.; Pomba, C.; Perreten, V. OXA-181-Producing Extra-Intestinal Pathogenic Escherichia coli ST410 Isolated from a Dog in Portugal. Antimicrob. Agents Chemother. 2020, 64, e02298-19.
  28. Pulss, S.; Stolle, I.; Stamm, I.; Leidner, U.; Heydel, C.; Semmler, T.; Prenger-Berninghoff, E.; Ewers, C. Multispecies and Clonal Dissemination of OXA-48 Carbapenemase in Enterobacteriaceae from Companion Animals in Germany, 2009–2016. Front. Microbiol. 2018, 9, 1265.
  29. Stolle, I.; Prenger-Berninghoff, E.; Stamm, I.; Scheufen, S.; Hassdenteufel, E.; Guenther, S.; Bethe, A.; Pfeifer, Y.; Ewers, C. Emergence of OXA-48 Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in Dogs. J. Antimicrob. Chemother. 2013, 68, 2802–2808.
  30. Melo, L.C.; Boisson, M.N.G.; Saras, E.; Médaille, C.; Boulouis, H.J.; Madec, J.Y.; Haenni, M. OXA-48-Producing ST372 Escherichia coli in a French Dog. J. Antimicrob. Chemother. 2017, 72, 1256–1258.
  31. Liu, X.; Thungrat, K.; Boothe, D.M. Occurrence of OXA-48 Carbapenemase and Other β-Lactamase Genes in ESBL-Producing Multidrug Resistant: Escherichia coli from Dogs and Cats in the United States, 2009–2013. Front. Microbiol. 2016, 7, 1057.
  32. Yousfi, M.; Touati, A.; Muggeo, A.; Mira, B.; Asma, B.; Brasme, L.; Guillard, T.; de Champs, C. Clonal Dissemination of OXA-48-Producing Enterobacter cloacae Isolates from Companion Animals in Algeria. J. Glob. Antimicrob. Resist. 2018, 12, 187–191.
  33. Pomba, C.; Endimiani, A.; Rossano, A.; Saial, D.; Couto, N.; Perreten, V. First Report of OXA-23-Mediated Carbapenem Resistance in Sequence Type 2 Multidrug-Resistant Acinetobacter baumannii Associated with Urinary Tract Infection in a Cat. Antimicrob. Agents Chemother. 2014, 58, 1267–1268.
  34. Ewers, C.; Klotz, P.; Leidner, U.; Stamm, I.; Prenger-Berninghoff, E.; Göttig, S.; Semmler, T.; Scheufen, S. OXA-23 and ISAba1–OXA-66 Class D β-Lactamases in Acinetobacter baumannii Isolates from Companion Animals. Int. J. Antimicrob. Agents 2017, 49, 37–44.
  35. World Health Organization (WHO). WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 16 April 2022).
  36. Schmiedel, J.; Falgenhauer, L.; Domann, E.; Bauerfeind, R.; Prenger-Berninghoff, E.; Imirzalioglu, C.; Chakraborty, T. Multiresistant Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae from Humans, Companion Animals and Horses in Central Hesse, Germany. BMC Microbiol. 2014, 14, 187.
  37. Moreira da Silva, J.; Menezes, J.; Salas, C.; Marques, C.; Teodoro, S.; Amaral, A.J.; Pomba, C. Clinical/Research Abstracts Accepted for Presentation at the ISFM 2021 World Feline Congress. J. Feline Med. Surg. 2021, 23, 851–858.
  38. Poirel, L.; Héritier, C.; Tolun, V.; Nordmann, P. Emergence of Oxacillinanse-Mediated Resistance to Imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2004, 48, 15–22.
  39. Kayama, S.; Koba, Y.; Shigemoto, N.; Kuwahara, R.; Kakuhama, T.; Kimura, K.; Hisatsune, J.; Onodera, M.; Yokozaki, M.; Ohge, H.; et al. Imipenem-Susceptible, Meropenem-Resistant Klebsiella pneumoniae Producing OXA-181 in Japan. Antimicrob. Agents Chemother. 2015, 59, 1379–1380.
  40. Kashyap, A.; Gupta, R.; Sharma, R.; Verma, V.V.; Gupta, S.; Goyal, P. New Delhi Metallo Beta Lactamase: Menace and Its Challenges. J. Mol. Genet. Med. 2017, 11, 299.
  41. Lee, C.R.; Lee, J.H.; Park, K.S.; Kim, Y.B.; Jeong, B.C.; Lee, S.H. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front. Microbiol. 2016, 7, 895.
  42. Farhat, N.; Khan, A.U. Evolving Trends of New Delhi Metallo-Betalactamse (NDM) Variants: A Threat to Antimicrobial Resistance. Infect. Genet. Evol. 2020, 86, 104588.
  43. Shanthi, M.; Sekar, U.; Arunagiri, K.; Goverdhandas Bramhne, H. OXA-181 Beta Lactamase Is Not a Major Mediator of Carbapenem Resistance in Enterobacteriaceae. J. Clin. Diagnostic Res. 2013, 7, 1986–1988.
  44. Mairi, A.; Pantel, A.; Sotto, A.; Lavigne, J.P.; Touati, A. OXA-48-like Carbapenemases Producing Enterobacteriaceae in Different Niches. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 587–604.
  45. Bakthavatchalam, Y.D.; Anandan, S.; Veeraraghavan, B. Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat. J. Glob. Infect. Dis. 2016, 8, 41–50.
  46. Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like Carbapenemases: The Phantom Menace. J. Antimicrob. Chemother. 2012, 67, 1597–1606.
  47. Gülmez, D.; Woodford, N.; Palepou, M.F.I.; Mushtaq, S.; Metan, G.; Yakupogullari, Y.; Kocagoz, S.; Uzun, O.; Hascelik, G.; Livermore, D.M. Carbapenem-Resistant Escherichia Coli and Klebsiella pneumoniae Isolates from Turkey with OXA-48-like Carbapenemases and Outer Membrane Protein Loss. Int. J. Antimicrob. Agents 2008, 31, 523–526.
  48. Poirel, L.; Bonnin, R.A.; Nordmann, P. Genetic Features of the Widespread Plasmid Coding for the Carbapenemase OXA-48. Antimicrob. Agents Chemother. 2012, 56, 559–562.
  49. Potron, A.; Nordmann, P.; Lafeuille, E.; Al Maskari, Z.; Al Rashdi, F.; Poirel, L. Characterization of OXA-181, a Carbapenem-Hydrolyzing Class D β-Lactamase from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2011, 55, 4896–4899.
  50. Turton, J.F.; Ward, M.E.; Woodford, N.; Kaufmann, M.E.; Pike, R.; Livermore, D.M.; Pitt, T.L. The Role of ISAba1 in Expression of OXA Carbapenemase Genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 2006, 258, 72–77.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback